Immunotherapy against amyloid pathology in Alzheimer's disease

Griffin, 2006, Inflammation and neurodegenerative diseases, Am J Clin Nutr, 3, 470S, 10.1093/ajcn/83.2.470S Galimberti, 2008, Inflammation in neurodegenerative disorders: friend or foe?, Curr Aging Sci, 1, 30, 10.2174/1874609810801010030 Reddy, 2009, Oxidative stress in diabetes and Alzheimer's disease, J Alzheimers Dis, 16, 763, 10.3233/JAD-2009-1013 Adlard, 2006, Metals and Alzheimer's disease, J Alzheimers Dis, 10, 145, 10.3233/JAD-2006-102-303 Stefani, 2009, Cholesterol in Alzheimer's disease: unresolved questions, Curr Alzheimer Res, 6, 15, 10.2174/156720509787313899 Lawrence, 1998, The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems, Neurochem Res, 23, 787, 10.1023/A:1022419712453 Farlow, 2002, A clinical overview of cholinesterase inhibitors in Alzheimer's disease, Int Psychogeriatr/IPA, 14, 93, 10.1017/S1041610203008688 Scarpini, 2011, Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial, J Alzheimers Dis, 26, 211, 10.3233/JAD-2011-110134 Birks, 2006, Cholinesterase inhibitors for Alzheimer's disease, Cochrane Database Syst Rev, 1, CD005593 Howard, 2012, Donepezil and memantine for moderate-to-severe Alzheimer's disease, N Engl J Med, 366, 893, 10.1056/NEJMoa1106668 Dhillon, 2011, Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type, Drugs, 71, 1209, 10.2165/11206380-000000000-00000 Raina, 2008, Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline, Ann Intern Med, 148, 379, 10.7326/0003-4819-148-5-200803040-00009 Alva, 2008, Relative tolerability of Alzheimer's disease treatments, Psychiatry (Edgmont), 5, 27 Goldgaber, 1987, Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease, Science, 235, 877, 10.1126/science.3810169 Kang, 1987, The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor, Nature, 325, 733, 10.1038/325733a0 Tanzi, 1987, Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus, Science, 235, 880, 10.1126/science.2949367 Vassar, 2004, BACE1: the beta-secretase enzyme in Alzheimer's disease, J Mol Neurosci, 23, 105, 10.1385/JMN:23:1-2:105 Allinson, 2003, ADAMs family members as amyloid precursor protein alpha-secretases, J Neurosci Res, 74, 342, 10.1002/jnr.10737 Edbauer, 2003, Reconstitution of gamma-secretase activity, Nat Cell Biol, 5, 486, 10.1038/ncb960 Koo, 2004, Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration, Nat Med, 10, S26, 10.1038/nm1065 Storey, 1996, The amyloid precursor protein of Alzheimer's disease is found on the surface of static but not activity motile portions of neurites, Brain Res, 735, 59, 10.1016/0006-8993(96)00609-9 Ho, 2004, Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage, Proc Natl Acad Sci U S A, 101, 2548, 10.1073/pnas.0308655100 Schenk, 1999, Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in PDAPP mouse, Nature, 400, 173, 10.1038/22124 Gilman, 2005, Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial, Neurology, 64, 1553, 10.1212/01.WNL.0000159740.16984.3C Hock, 2005, Clinical observations with AN1792 using TAPIR analyses, Neurodegener Dis, 2, 273, 10.1159/000090368 Holmes, 2008, Long-term effect of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial, Lancet, 372, 216, 10.1016/S0140-6736(08)61075-2 Nicoll, 2003, Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report, Nat Med, 9, 448, 10.1038/nm840 Ferrer, 2004, Neuropathology and pathogenesis of encephalitis following amyloid β immunization in Alzheimer's disease, Brain Pathol, 14, 11, 10.1111/j.1750-3639.2004.tb00493.x Monsonego, 2003, Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease, J Clin Invest, 112, 415, 10.1172/JCI200318104 Winblad, 2012, Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study, Lancet Neurol, 11, 597, 10.1016/S1474-4422(12)70140-0 Farlow, 2012, Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, Alzheimers Dement, 8, 261, 10.1016/j.jalz.2011.09.224 Relkin, 2009, 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease, Neurobiol Aging, 30, 1728, 10.1016/j.neurobiolaging.2007.12.021 Hughes, 2009, Clinical applications of intravenous immunoglobulins in neurology, Clin Exp Immunol, 158, 34, 10.1111/j.1365-2249.2009.04025.x Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol, 6, 734, 10.1016/S1474-4422(07)70178-3 Galimberti, 2011, Alzheimer's disease: from pathogenesis to disease-modifying approaches, CNS Neurol Disord Drug Targets, 10, 163, 10.2174/187152711794480438